TY - JOUR
T1 - Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvement
AU - Moreno Martinez, Maria Estela
AU - Riba, Mireia
AU - Garcia Cadenas, Irene
AU - Esquirol, Albert
AU - Yusta, Marta
AU - Redondo, Sara
AU - De Dios, Anna
AU - Portos, José Manuel
AU - Aso, Olga
AU - Marcos Fendian, Ángel
AU - Font, Núria
AU - Briones Meijide, Javier
AU - Martino Bofarull, Rodrigo
AU - Feliu, Anna
N1 - Publisher Copyright:
Copyright © 2024 Moreno-Martinez, Riba, García-Cadenas, Esquirol, Yusta, Redondo, De Dios, Portos, Aso, Marcos-Fendian, Font, Briones, Martino and Feliu.
PY - 2024/6/11
Y1 - 2024/6/11
N2 - Home hospitalization represents an alternative to traditional hospitalization, providing comparable clinical safety for hematological patients. At-home therapies can range from the delivery of intravenous antibiotics to more complex scenarios, such as the care during the early period after hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy. Early discharge from conventional hospitalization is feasible and helps reduce hospital resources and waiting lists. The coordinated efforts of multidisciplinary teams, including hematologists, nurses, and pharmacists, ensure patient safety and continuity of care. The traditional model of home hospitalization relies on home visits and telephone consultations with physicians and nurses. However, the use of eHealth technologies, such as MY-Medula, can enhance communication and monitoring, and thereby improve patient outcomes with no additional costs. The active involvement of a clinical pharmacist in home hospitalization programs is essential, not only for the proper logistical management of the medication but also to ensure its appropriateness, optimize treatment, address queries from the team and patients, and promote adherence. In conclusion, the implementation of hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy home hospitalization programs that use both an eHealth tool and a multidisciplinary care model can optimize patient care and improve quality of life without increasing healthcare costs.
AB - Home hospitalization represents an alternative to traditional hospitalization, providing comparable clinical safety for hematological patients. At-home therapies can range from the delivery of intravenous antibiotics to more complex scenarios, such as the care during the early period after hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy. Early discharge from conventional hospitalization is feasible and helps reduce hospital resources and waiting lists. The coordinated efforts of multidisciplinary teams, including hematologists, nurses, and pharmacists, ensure patient safety and continuity of care. The traditional model of home hospitalization relies on home visits and telephone consultations with physicians and nurses. However, the use of eHealth technologies, such as MY-Medula, can enhance communication and monitoring, and thereby improve patient outcomes with no additional costs. The active involvement of a clinical pharmacist in home hospitalization programs is essential, not only for the proper logistical management of the medication but also to ensure its appropriateness, optimize treatment, address queries from the team and patients, and promote adherence. In conclusion, the implementation of hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy home hospitalization programs that use both an eHealth tool and a multidisciplinary care model can optimize patient care and improve quality of life without increasing healthcare costs.
KW - Care model
KW - Chimeric antigen receptor T-cell
KW - Clinical pharmacist
KW - Ehealth
KW - Hematopoietic stem cell transplantation
KW - Hospital-based home care
UR - https://www.scopus.com/pages/publications/85196776005
U2 - 10.3389/fimmu.2024.1397115
DO - 10.3389/fimmu.2024.1397115
M3 - Article
C2 - 38919607
SN - 1664-3224
VL - 15
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1397115
ER -